 "Dr Reddy's Lab rallies on launch of Nexium's generic version")
Dr Reddy’s Laboratories has rallied 6% to Rs 4,223 on the BSE in otherwise subdued market after the drug maker announced the launch of Esomeprazole Magnesium Delayed-release capsules, which is the generic version of AstraZeneca's Nexium, in the US market.
“The company has launched Esomeprazole Magnesium Delayed-Release Capsules USP 20 mg and 40 mg, a therapeutic equivalent generic version of AstraZeneca Plc's Nexium in the US market on September 25, 2015, following the approval by the United States Food & Drug Administration (USFDA),” Dr Reddy’s Laboratories said in a press release.
The Nexium® (esomeprazole magnesium) Delayed-Release capsules brand and generic had U.S. sales of approximately $5.2 billion MAT for the most recent 12 months ending July 2015, according to IMS Health.
At 10:52 a.m., the stock was up 5.3% at Rs 4,182 on the BSE. The trading volumes on the counter more than doubled with a combined 448,787 shares changed hands on the BSE and NSE so far.
“The company has launched Esomeprazole Magnesium Delayed-Release Capsules USP 20 mg and 40 mg, a therapeutic equivalent generic version of AstraZeneca Plc's Nexium in the US market on September 25, 2015, following the approval by the United States Food & Drug Administration (USFDA),” Dr Reddy’s Laboratories said in a press release.
The Nexium® (esomeprazole magnesium) Delayed-Release capsules brand and generic had U.S. sales of approximately $5.2 billion MAT for the most recent 12 months ending July 2015, according to IMS Health.
At 10:52 a.m., the stock was up 5.3% at Rs 4,182 on the BSE. The trading volumes on the counter more than doubled with a combined 448,787 shares changed hands on the BSE and NSE so far.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%